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Abstract
Objective To determinate the prevalence and correlates
of cardiometabolic multimorbidity (CMM), and their crosscountry variation among individuals with hypertension
residing in rural communities in South Asia.
Design A cross-sectional study.
Setting Rural communities in Bangladesh, Pakistan and
Sri Lanka.
Participants A total of 2288 individuals with hypertension
aged ≥40 years from the ongoing Control of Blood
Pressure and Risk Attenuation- Bangladesh, Pakistan and
Sri Lanka clinical trial.
Main outcome measures CMM was defined as the
presence of ≥2 of the conditions: diabetes, chronic kidney
disease, heart disease and stroke. Logistic regression was
done to evaluate the correlates of CMM.
Results About 25.4% (95% CI 23.6% to 27.2%) of the
hypertensive individuals had CMM. Factors positively
associated with CMM included residing in Bangladesh
(OR 3.42, 95% CI 2.52 to 4.65) or Sri Lankan (3.73, 95%
CI 2.48 to 5.61) versus in Pakistan, advancing age (2.33,
95% CI 1.59 to 3.40 for 70 years and over vs 40–49
years), higher waist circumference (2.15, 95% CI 1.42
to 3.25) for Q2–Q3 and 2.14, 95% CI 1.50 to 3.06 for
Q3 and above), statin use (2.43, 95% CI 1.84 to 3.22),
and higher levels of triglyceride (1.01, 95% CI 1.01 to
1.02 per 5 mg/dL increase). A lower odds of CMM was
associated with being physically active (0.75, 95% CI 0.57
to 0.97). A weak inverted J-shaped association between
International Wealth Index and CMM was found (p for nonlinear=0.058), suggesting higher risk in the middle than
higher or lower socioeconomic strata.
Conclusions CMM is highly prevalent in rural South
Asians affecting one in four individuals with hypertension.
There is an urgent need for strategies to concomitantly
manage hypertension, cardiometabolic comorbid
conditions and associated determinants in South Asia.
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end of article.
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Introduction
Cardiometabolic multimorbidity (CMM),
defined as the coexistence of two or more of

Strengths and limitations of this study
►► This study is the first to evaluate the prevalence and

correlates of cardiometabolic multimorbidity (CMM)
in a representative sample aged ≥40 years with hypertension from rural communities in Bangladesh,
Pakistan and Sri Lanka.
►► Our study used a uniform study design, door-todoor sampling of individuals, random selection of
clusters, consistent definitions of variables and outcomes (eg, standardised measurements of serum
creatinine) and standardised study procedures in all
three countries.
►► A causal relationship between covariates and CMM
cannot be inferred due to the cross-sectional design
of the study.
►► We did not have data on covariates such as healthcare access, dietary habit, psychological stress and
physiological biomarkers, which may additionally
explain cross-country variation in multimorbidity.
►► Our findings may not be generalised to all rural-residing hypertensive individuals aged 40 years and
over in each country.

the following chronic conditions (diabetes,
heart disease, stroke and chronic kidney
disease (CKD)), is being increasingly
recognised as a global public health challenge.1 2 Compared with a single cardiometabolic disease, multimorbidity from these
conditions is associated with multiplicative
risk of mortality and cognitive decline.1 3
Individuals from South Asia have been
shown to be more susceptible to cardiometabolic and other chronic conditions compared
with other ethnic groups.4 5 In part, this is
postulated to be due to higher visceral fat
mass as South Asians have been shown to
have higher amounts of abdominal adipose
than Caucasians,6 7 and abdominal obesity is
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better predictors for cardiovascular diseases (CVDs) risk
and diabetes than body mass index (BMI).8 Furthermore,
most of South Asia is still rural with significant disparities in access to healthcare, and mortality from CVD has
shown to be higher than in urban areas.9 However, the
prevalence and correlates of CMM in rural South Asian
countries have not been reported.
Therefore, we analysed baseline data from the ongoing
Control of Blood Pressure and Risk Attenuation- Bangladesh, Pakistan and Sri Lanka (COBRA-BPS) trial on 2288
hypertensive individuals in rural communities in Bangladesh, Pakistan and Sri Lanka with the following objectives:
(1) To examine the prevalence of CMM, (2) to determine
the sociodemographic characteristics, lifestyle factors and
clinical risk factors associated with CMM. We also sought
to determine whether BMI or waist circumference was a
stronger determinant of CMM in this population.
We hypothesised that: (1) the prevalence of CMM is
high, and varies among hypertensive individuals in rural
communities across the three South Asian countries; (2)
the cross-country variation in CMM will only partially be
accounted for by differences in sociodemographic, lifestyle and clinical risk factors and (3) waist circumference
will be more strongly associated with CMM than BMI.
Methods
Population
The present study was performed using the baseline data
from COBRA-BPS full-scale study. The study methodology
has been described previously.10 Briefly, COBRA-BPS
full-scale study is an ongoing 2-year cluster randomised
controlled trial among 2643 hypertensive adults from
30 randomly selected rural clusters (communities), 10
clusters each, in Bangladesh, Pakistan and Sri Lanka. In
each country, clusters selection was stratified by distance
(≤2.5 km for near and >2.5 for far) from the government
primary care clinics such that there were six near and four
far clusters in each country. Individuals in each cluster
were screened using door-to-door sampling method. The
inclusion criteria for COBRA-BPS were age ≥40 years,
hypertension (defined as a sustained elevation of systolic
blood pressure (BP) to ≥140 mm Hg, or diastolic BP to
≥90 mm Hg based on two readings from 2o separate days,
or receiving antihypertensive medications), and residents
in the selected clusters. Individuals were excluded if
they had severe physical incapacity, were pregnant, had
advanced diseases (on dialysis, liver failure and other
systemic diseases) or mentally comprised leading to the
incapability of giving consent.
Online supplementary figure S1 shows the study flow
diagram. Of the 2977 hypertensive individuals from 30
randomly selected clusters in 3 countries, 2643 were
enrolled in the clinical trial after excluding 334 individuals
for various reasons (see online supplementary figure S1).
Of the 2643 hypertensives recruited, 355 (13.4%) were
excluded because they missed data on diabetes (n=217),
CKD (n=289) and heart disease (n=64), leaving 2288 for
2

the final analysis. The study protocol was approved by the
relevant Ethical Review Committee in Singapore, Bangladesh, Pakistan, Sri Lanka, and the UK. All study participants provided written informed consent.
Measurements
Sociodemographic variables were age (40–49, 50–59,
60–69, 70 and over years), gender, education (formal vs
informal education) and marital status (married vs single,
divorced or widowed). Economic status was assessed by
International Wealth Index (IWI).11 IWI is based on a
household’s ownership of selected assets, access to basic
service and characteristics of the house and is estimated
by principal component analysis. The score of IWI ranges
from 0 to 100 and, in the current study, was classified
into four groups via its quartiles (IWI<43, 43≤IWI<60,
60≤IWI<73 and IWI≥73). Lifestyle factors included
smoking status (current smoker vs non-current smoker)
and physical activity. Physical activity was evaluated by
the short version of the International Physical Activity
Questionnaire12 and was classified as inactive, minimally
active and highly active. BMI was calculated as weight (in
kilogram)/height (in metres)2 and was categorised as
underweight (BMI <18.5), normal (18.5≤BMI<23), overweight (23≤BMI<27.5) and obesity (BMI ≥27.5).13 Waist
circumference was grouped into four categories using
the gender-specific quartiles (for male ≤82, 82–91, 91–98,
≥98 cm, for female ≤79, 79–88, 88–95 and ≥95 cm). Heart
disease was ascertained based on self-reported physician
diagnosis of angina, heart attack and heart failure. Stroke
was determined according to WHO definition.14 Family
history of CVD was determined according to self-reported
family history of heart disease or stroke.
An overnight fasting blood sample was collected to
measure serum creatinine (measured on Beckman DU),
lipids (measured on Roche Hitachi-912) and plasma
glucose (measured on Beckman Synchron Cx-7/Delta)
in each country. Serum creatinine measurements were
calibrated to isotope dilution mass spectrometry traceable values. Urine albumin and creatinine excretion were
measured on spot urine samples by nephelometry using
the Array Systems method on a Beckman Coulter. All tests
were done in an accredited laboratory in each country.
Although no variability study was done for the tests, all
three laboratories conformed to international standards
for diagnostics. Diabetes was defined as a fasting plasma
glucose ≥126 mg/dL or self-reported use of antidiabetic
medication. CKD was defined as the presence of estimated
glomerular filtration rate (GFR) ≤60 mL/min/1.73 m2 or
urine albumin and creatinine ratio (UACR) ≥30 mg/g.
GFR was estimated using the original CKD- Epidemiology
Collaboration equation.15 UACR was determined by urine
albumin divided by urine creatinine.
Statistical analysis
The outcome measurement of this study was the presence of CMM, defined as having two or more of the
following cardiometabolic conditions: diabetes, CKD,
Feng L, et al. BMJ Open 2019;9:e030584. doi:10.1136/bmjopen-2019-030584
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heart disease and stroke. CKD was included in the definition because it has a strong association with CVD due to
traditional cardiovascular risk factors (eg, hypertension
and diabetes), and kidney-specific risk factors (eg, dyslipidaemia, anaemia and low-grade inflammation).16
The comparison of characteristics between individuals
with and without CMM was performed using independent sample t-test for continuous variables and χ2 test for
categorical variables. When continuous variables were not
normally distributed, Mann-Whitney U test was used. We
used Cochran-Armitage trend test to measure the association of waist circumference categories with different
measurements of cardiometabolic conditions—individual and multimorbid.
We fitted generalised estimating equation logistic regression models with an exchangeable correlation matrix for
CMM to account for the hierarchical nature of the data
within the villages (clusters) in each country. ORs and
95% CIs were presented. Covariates considered clinically
relevant or found to be associated with CMM in previous
literature or in the current bivariate analysis at p<0.15
were included in the multivariate models. Three models
were built by sequentially entering the covariates in three
individual blocks. In model 1, only country was included;
in model 2, we included age, gender, education, marital
status, IWI and BMI besides country; in the last model,
we additionally added physical activity, smoking, waist
circumference, family history of CVD, statin use, high-density lipoprotein (HDL), low-density lipoprotein (LDL)
and triglyceride. Total cholesterol was not included in the
model due to its strong correlation with LDL (Pearson
correlation coefficient=0.90). Because adjusted analysis
suggested possible non-linear associations of CMM with
IWI and waist circumference, we further examined their
associations with the restricted cubic splines by modelling the two covariates as continuous variables.17 We used
‘%RCS_Reg’ SAS macro18 to perform adjusted analysis
with five knots (5%, 25%,50%,75% and 95% percentiles)
specified.
We also investigated two-way interactions between
country and other variables in the last model to assess the
presence of a country-specific effect. Significant interactions were interpreted by the ratio of ORs (RORs)19 and
subgroup analysis by country.
All analyses were conducted using SAS V.9.4, and all
hypothesis testing was two tailed with p<0.05 set as statistically significant.
Patient and public involvement statement
Patients and public were not involved in the conception,
design or interpretation of this study.

Results
Baseline characteristics
The baseline characteristics of 2288 individuals with
hypertension are shown in table 1. The overall prevalence
of CMM was 25.3% (n=581). The mean (SD) age was 59.0
Feng L, et al. BMJ Open 2019;9:e030584. doi:10.1136/bmjopen-2019-030584

(11.3) years; 64.3% (n=1471) were female. The mean
(SD) BMI and waist circumference were 24.7 (5.0) kg/m2
and 88.2 (12.8) cm, respectively.
Individuals with CMM were older, better educated,
less likely to be married and had higher IWI scores than
were those without. They also had lower levels of physical activity, higher BMI, higher waist circumference and
elevated levels of triglyceride, and were more likely to
have a family history of CVD, to be Sri Lankan and statin
users. In contrast, no other baseline characteristics were
associated with CMM (table 1).
Online supplementary table S1 shows the characteristics of individuals included (n=2288) and excluded
(n=355) from the current analysis. Compared with individuals excluded, those included had higher education,
higher IWI score, higher levels of physical activity, and
were more likely to have a family history of CVD, reside
in Bangladesh and Sri Lanka, and use statin. Country-specific baseline characteristics are summarised in online
supplementary tables S2–4.
CMM conditions
Table 2 shows bivariate associations between various
measurements of cardiometabolic conditions and waist
circumference quartiles. Hypertensive individuals with
a single additional cardiometabolic condition and
three or more cardiometabolic conditions accounted
for 35.3% (95% CI 33.3% to 37.3%) and 5.6% (95% CI
4.7% to 6.7%), respectively. CKD was the most prevalent
cardiometabolic condition (38.3%, 95% CI 36.3% to
40.3%).
CMM and waist circumference
The prevalence of CMM increased across the first three
quartile groups of waist circumference, and slightly
dropped in the highest quartile (p value for linear trend
<0.001) (table 2). We also observed a significant linear
trend for three or more cardiometabolic conditions,
diabetes, heart disease and stroke, but not for CKD
(table 2). Corresponding country-specific results are
reported in online supplementary tables S5–7. CMM
was most prevalent among participants from Sri Lanka
(36.3%, 95% CI 33.0% to 39.8%), followed by those from
Bangladesh (27.4%, 95% CI 24.3% to 30.5%) and Pakistan (10.2%, 95% CI 8.0% to 12.7%).
The bivariate associations between morbidity pairs
and waist circumference are presented in online supplementary table S8. The most frequently observed pair was
diabetes and CKD (10.1%, 95% CI 8.9% to 11.4%), and
least observed was diabetes and stroke (1.2%, 95% CI
0.8% to 1.7%). An increasing trend across the quartile
groups of waist circumference was observed for coexisting diabetes and CKD (p for linear trend <0.001).
Diabetes and CKD were also the most prevalent pair in all
three countries, but the prevalence of other pairs in each
country differed from that of the whole sample and each
other (see online supplementary tables S9–11).
3
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Table 1 Baseline characteristics by status of cardio-metabolic multimorbidity* (n=2288)
Cardiometabolic multimorbidity
Characteristics

All

Yes (n=581)

No (n=1707)

Age (y), n (%)

P value
<0.001

 40–49

566 (24.7)

92 (15.8)

474 (27.8)

.

 50–59

633 (27.7)

138 (23.8)

495 (29.0)

.

 60–69

660 (28.8)

203 (34.9)

457 (26.8)

.

 70 and over

429 (18.8)

148 (25.5)

281 (16.5)

.

Male, n (%)

817 (35.7)

217 (37.3)

600 (35.1)

0.34

Formal education (vs informal), n (%)

1396 (61.0)

431 (74.2)

965 (56.5)

<0.001

Married (vs others), n (%)

1679 (73.4)

399 (68.7)

1280 (75.0)

0.003

 0–43

539 (23.6)

83 (14.3)

456 (26.8)

.

 43–60

596 (26.1)

158 (27.2)

438 (25.7)

.

 60–73

555 (24.3)

159 (27.4)

396 (23.3)

.

 73 and above

591 (25.9)

180 (31.0)

411 (24.2)

.

Current smoker (vs current non-smoker), n (%)

236 (10.3)

55 (9.5)

181 (10.6)

International Wealth Index score, n (%)

<0.001

Physical activity level (MET-min/week), n (%)

0.44
<0.001

 Inactive

603 (26.7)

157 (27.5)

446 (26.4)

.

 Minimally active

512 (22.7)

164 (28.7)

348 (20.6)

.

1144 (50.6)

250 (43.8)

894 (53.0)

.

 <18.5

204 (8.9)

29 (5.0)

175 (10.3)

.

 18.5–23.0

656 (28.7)

166 (28.7)

490 (28.8)

.

 23.0–27.5

849 (37.2)

231 (39.9)

618 (36.3)

.

 27.5 and above

573 (25.1)

153 (26.4)

420 (24.7)

 Highly active
2

BMI (kg/m ), n (%)

0.001

Waist circumference† (cm), n (%)

.
<0.001

 0–Q1

543 (23.8)

93 (16.0)

450 (26.4)

.

 Q1–Q2

570 (24.9)

139 (24.0)

431 (25.3)

.

 Q2–Q3

554 (24.2)

174 (30.0)

380 (22.3)

.

 Q3 and above

619 (27.1)

174 (30.0)

445 (26.1)

Family history of CVD, n (%)

593 (26.5)

177 (31.3)

416 (24.9)

 Bangladesh

819 (35.8)

224 (38.6)

595 (34.9)

.

 Pakistan

679 (29.7)

70 (12.0)

609 (35.7)

.

 Sri Lanka

790 (34.5)

287 (49.4)

503 (29.5)

Country, n (%)

HDL (mg/dL), mean (SD)

.
0.003
<0.001

45.3 (12.8)

45.3 (12.8)

45.3 (12.8)

Triglyceride (mg/dL), median (IQR)

128.7 (94.0,183.0)

132.8 (99.3,192.0)

127.0 (91.8,179.1)

Total cholesterol (mg/dL), mean (SD)

194.6 (48.5)

197.4 (52.0)

193.6 (47.2)

LDL (mg/dL), mean (SD)

124.4 (40.6)

124.0 (43.8)

124.5 (39.4)

Statin use, n (%)

315 (13.8)

156 (26.9)

159 (9.3)

.
0.98
<0.001
0.12
0.82
<0.001

*For male ≤82, 82–91, 91–98, ≥98 cm, for female ≤79, 79–88, 88–95, ≥95 cm.
†Cardiometabolic multimorbidity was defined as as the presence of two or more chronic conditions of diabetes, heart disease, CKD and stroke.
BMI, body mass index;CKD, chronic kidney disease; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET,
metabolic equivalent of task.

Factors associated with CMM
In multivariate-adjusted analysis, living in Bangladesh or
Sri Lanka (vs Pakistan), older age, higher IWI, higher
waist circumference, statin use and elevated levels of
triglyceride were significantly associated with a higher
4

odds of CMM, while being physically active was associated
with a lower odds of CMM (model 3 in table 3). BMI was
not significantly associated with CMM in model 3. The
evaluation for interaction showed that country significantly modified the associations between CMM and four
Feng L, et al. BMJ Open 2019;9:e030584. doi:10.1136/bmjopen-2019-030584
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622 (27.2 (25.4 to 29.1))

317 (13.9 (12.5 to 15.4))
293 (12.8 (11.5 to 14.3))

Diabetes‡

Heart disease§
Stroke¶

45 (8.3 (6.1 to 10.9))
85 (15.7 (12.7 to 19.0))

61 (11.2 (8.7 to 14.2))

208 (38.3 (34.2 to 42.5))

84 (14.7 (11.9 to 17.9))
70 (12.3 (9.7 to 15.3))

140 (24.6 (21.1 to 28.3))

213 (37.4 (33.4 to 41.5))

27 (4.7 (3.1 to 6.8))

199 (34.9 (31.0 to 39.0))

139 (24.4 (20.9 to 28.1))

Q1–Q2
(n=570)

105 (19.0 (15.8 to 22.5))
79 (14.3 (11.5 to 17.5))

190 (34.3 (30.3 to 38.4))

218 (39.4 (35.3 to 43.6))

44 (7.9 (5.8 to 10.5))

196 (35.4 (31.4 to 39.5))

174 (31.4 (27.6 to 35.5))

Q2–Q3
(n=554)

*Cardiometabolic multimorbidity was defined as the presence of two or more chronic conditions of diabetes, heart disease, CKD and stroke.
†CKD was defined as the presence of estimated glomerular filtration rate ≤60 mL/min/1.73 m2 or urine albumin and creatinine ratio ≥30 mg/g.
‡Diabetes was defined as a fasting plasma glucose ≥126 mg/dL or self-reported use of antidiabetic medication.
§Heart disease was acertained based on self-reported physician diagnosis.
¶Stroke was determined if an invidual ever had unconciousness or had both abnormal speech and paralysed face.
** Cardiometabolic conditions included diabetes, heart disease, CKD and stroke.

875 (38.3 (36.3 to 40.3))

Chronic kidney disease
(CKD)†

15 (2.8 (1.6 to 4.5))

198 (36.5 (32.4 to 40.7))

807 (35.3 (33.3 to 37.3))

129 (5.6 (4.7 to 6.7))

93 (17.1 (14.1 to 20.6))

580 (25.4 (23.6 to 27.2))

Three or more
cardiometabolic conditions

Cardiometabolic
multimorbidity*
Single cardiometabolic
condition

0–Q1
(n=543)

83 (13.4 (10.8 to 16.3))
59 (9.5 (7.3 to 12.1))

231 (37.3 (33.5 to 41.3))

236 (38.1 (34.3 to 42.1))

43 (6.9 (5.1 to 9.2))

214 (34.6 (30.8 to 38.5))

174 (28.1 (24.6 to 31.8))

Q3 and over
(n=619)

Prevalence of cardiometabolic conditions stratified by quartiles of waist circumference among all individuals with hypertension (n=2286)

Cardiometabolic
Total
conditions**, n (% (95% CI)) (n=2286)

Table 2

0.005
0.008

<0.001

0.88

<0.001

0.56

<0.001

P value
for
trend
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Table 3 Multivariate predictors of cardiometabolic multimorbidity among hypertensive individuals in rural Bangladesh,
Pakistan and Sri Lanka
Model 1 (n=2288)
Variables

OR (95% CI)

Country

Model 2 (n=2275)
P value

OR (95% CI)

<0.001

Model 3 (n=2191)
P value

OR (95% CI)

<0.001
1.00

P value
<0.001

 Pakistan

1.00

1.00

 Bangladesh

3.28 (2.41 to 4.47)

<0.001

3.22 (2.41 to 4.29)

<0.001

3.42 (2.52 to 4.65)

<0.001

 Sri Lanka

4.98 (3.76 to 6.58)

<0.001

3.40 (2.50 to 4.63)

<0.001

3.73 (2.48 to 5.61)

<0.001

Age (year)

<0.001

<0.001

 40–49

1.00

1.00

 50–59

1.35 (0.99 to 1.86)

0.060

1.29 (0.94 to 1.77)

0.12

 60–69

2.08 (1.51 to 2.86)

<0.001

1.82 (1.31 to 2.53)

<0.001

 70 and over

2.59 (1.81 to 3.70)

<0.001

2.33 (1.59 to 3.40)

<0.001

Gender

0.32

 Male

1.00

 Female

0.86 (0.63 to 1.16)

0.58
1.00

Education

0.32

0.92 (0.67 to 1.25)

0.046

 Informal

1.00

 Formal

1.29 (1.00 to 1.64)

0.58
0.17

1.00

Marital status

0.046

1.20 (0.93 to 1.56)

0.15

 Single or widowed or divorced

1.00

 Married

0.82 (0.63 to 1.08)

0.17
0.18

1.00

International Wealth Index score

0.15

0.82 (0.62 to 1.10)

0.025

0.18
0.014

 0–43

1.00

1.00

 43–60

1.60 (1.11 to 2.31)

0.012

1.63 (1.09 to 2.44)

0.018

 60–73

1.64 (1.14 to 2.36)

0.008

1.69 (1.12 to 2.55)

0.013

 73 and above

1.38 (0.93 to 2.04)

0.11

1.29 (0.84 to 1.97)

0.25

2

BMI (kg/m )

<0.001

0.24

 <18.5

1.00

1.00

 18.5–23.0

1.85 (1.30 to 2.65)

<0.001

1.17 (0.78 to 1.76)

0.45

 23.0–27.5

2.13 (1.45 to 3.14)

<0.001

0.90 (0.57 to 1.42)

0.65

 27.5 and above

2.44 (1.62 to 3.66)

<0.001

0.89 (0.56 to 1.41)

0.61

Smoking

0.87

 Non-current smoker

1.00

 Current smoker

1.04 (0.66 to 1.64)

Physical activity level (MET-min/
week)

0.87
0.010

 Inactive

1.00

 Minimally active

0.97 (0.71 to 1.30)

 Highly active

0.75 (0.57 to 0.97)

Waist circumference* (cm)

0.82
0.029
<0.001

 0–Q1

1.00

 Q1–Q2

1.43 (1.03 to 1.99)

0.033

 Q2–Q3

2.15 (1.42 to 3.25)

<0.001

 Q3 and above

2.14 (1.50 to 3.06)

<0.001

Family history of CVD

0.55

 No

1.00

 Yes

1.08 (0.84 to 1.37)

Statin use
 Non-user

0.55
<0.001

1.00

Continued
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Table 3 Continued
Model 1 (n=2288)
Variables

OR (95% CI)

Model 2 (n=2275)
P value

OR (95% CI)

Model 3 (n=2191)
P value

OR (95% CI)

P value

 User

2.43 (1.84 to 3.22)

<0.001

HDL (mg/dL, per 5 mg/dL increase)

0.96 (0.89 to 1.02)

0.17

Triglyceride(mg/dL, per 5 mg/dL
increase

1.01 (1.01 to 1.02)

<0.001

LDL (mg/dL, per 5 mg/dL increase)

1.00 (0.98 to 1.01)

0.57

*For male ≤82, 82–91, 91–98, ≥98 cm, for female ≤79, 79–88, 88–95, ≥95 cm.
BMI, body mass index; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic equivalent of task.

other covariates: age (p for interaction<0.001), history
of CVD (p for interaction=0.012), HDL (p for interaction=0.008) and statin use (p for interaction=0.006) (see
online supplementary tables S12 and 13). These associations varied in strength but not direction across the three
countries. Multivariable-adjusted restricted cubic spline
analyses suggested no evidence of a non-linear association
between waist circumference and CMM (p for non-linear
trend=0.59 based on model 3) but a weak non-linear
association between IWI and CMM (figure 1A, inverted
J-shaped, p for non-linear trend=0.058 based on model 3,
and figure 1B, p for non-linear trend=0.026 based on the
model adjusted for only age and gender.
Discussion
Data on multimorbidity are limited from South Asian
countries.20–25 This study is the first to evaluate the prevalence and correlates of CMM in a representative sample
aged ≥40 years with hypertension from rural communities in Bangladesh, Pakistan and Sri Lanka. We observed
an alarmingly high prevalence of CMM—up to 25%—in
rural South Asians with hypertension, and it was higher
in Sri Lanka than the other two countries. CKD was the
most common comorbid condition, followed by diabetes,

stroke and heart disease. CKD and diabetes dominated all
the morbidity pairs, and were found in 10% of the population with hypertension. Individuals residing in Bangladesh and Sri Lanka (vs Pakistan) had higher odds of
CMM regardless of sociodemographics, economic status,
lifestyles and clinical factors. Being older, lower levels of
physical activity, higher waist circumference, lower levels
of HDL and higher levels of triglyceride, each, were independently associated with the presence of CMM. Waist
circumference was a stronger correlate of CMM than
BMI. An inverted J-shaped association was found between
IWI and the odds of CMM. Our findings add to the
current knowledge on the epidemiology of CMM in rural
South Asians, and underscore the importance to develop
prevention and treatment strategies to target individuals
at risk of or with CMM.
There are very few reports on CMM from South Asia,
and the types of conditions vary. In a study from urban
areas of Delhi, Chennai and Karachi, 9.4% of adults aged
≥20 years had two or more of hypertension, diabetes,
heart disease, stroke and CKD.25 Our study in hypertensive community dwellers from rural areas in three South
Asian countries indicated a higher prevalence with one
in four individuals having two additional cardiometabolic

Figure 1 Multiple-adjusted log (ORs) and 95% CIs of cardiometabolic multimorbidity with International Wealth Index Score. A
was based on model 3 in table 3, while B was derived based on the model adjusted for only age and gender.
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comorbid conditions. CKD was the most prevalent
comorbid condition, partially attributable to the high
prevalence of diabetes and other factors,26 which deserves
further study. The implications of findings are significant
as health systems are more fragmented in rural compared
with urban areas, highlighting the urgency to provide
comprehensive services for vascular disease prevention
and management in rural South Asia.
It is interesting that we found an inverted J-shaped association between socioeconomic status and CMM, which
is in contrast with studies in developed countries showing
that lower economic status was a risk factor for multimorbidity.27–29 Studies from low-income and middle- income
countries show a positive association of chronic non-communicable diseases with a socioeconomic gradient.22 24 30
However, the non-linear relationship of CMM in our study
suggested that cardiometabolic risk was highest in those in
the middle socioeconomic strata (SES), compared with the
highest and the lowest quartile of SES. The latter finding
may be suggestive of an early reversal of social gradient for
CMM and is consistent with our earlier finding of higher
odds of uncontrolled hypertension in this population,31 and
other studies showing more rich patients receive treatment
including antihypertensive medications in India.32
Our study demonstrated that waist circumference had
a stronger association with CMM than BMI because waist
circumference but not BMI was statistically significant in
the fully adjusted model (model 3 in table 3) Earlier studies
have shown a clear incremental association of abdominal
obesity over BMI for non-fatal myocardial infarction, stroke,
diabetes and CKD.33–36 Also, a strong association of renal
function decline with central obesity and BMI has been
reported in a recent meta-analysis of 39 general population
cohorts from 40 countries.37 Taken together, our findings
suggest that central obesity should probably be included in
multimorbidity indices in Asians, and especially underscore
the same for adults with hypertension.38
Our findings also showed a remarkable variation in
the prevalence of CMM among the three countries, with
the highest in Sri Lanka and the lowest in Pakistan. Both
CKD and diabetes were much more prevalent in Sri
Lanka than the other two countries, which was the main
reason for the higher prevalence of multimorbidity in Sri
Lanka. Moreover, the variation in the prevalence could
not be fully explained by sociodemographics, economic
status, lifestyles and clinical factors, suggestive of the
presence of residual confoundings. CKD of unknown
aetiology is more prevalent in Sri Lanka39 and could
be caused by the interaction of multiple agents such as
heavy metals, pesticides, native (ayurvedic) medications
or infections.39 40
Our alarmingly high rate of CMM in rural South Asia
has major implications for public health at the national,
regional and global levels. Our findings call for urgent
programme to institute preventive measures to address
hypertension and associated multimorbidity in rural
areas in these countries where poor access to treatment
and high CVD mortality rates have been reported.9 41
8

The major strengths of our study are that we used a
uniform study design, door-to-door sampling of individuals, random selection of clusters, consistent definitions of
variables and outcomes (eg, standardised measurements
of serum creatinine), and standardised study procedures
in all three countries. This study also has limitations. First,
a causal relationship between covariates and CMM cannot
be inferred due to the cross-sectional design of the study.
Therefore, the observed association between obesity and
CMM could be underestimated because multimorbidity
can cause subsequent weight loss. Second, heart disease
was ascertained based on self-reported physician diagnosis
and stroke based on self-reported signs and symptoms of
stroke, which may be subject to information bias. Third,
we allocated equal weight to each chronic condition in
terms of disease severity. In fact, the effects of multimorbidity on various domains of health are likely to depend
on disease severity, the unique combination of diseases
and access to treatment and support.42 Fourth, we did not
have data on covariates such as healthcare access, dietary
habit, psychological stress and physiological biomarkers,
which may additionally explain cross-country variation
in multimorbidity. However, the main objective of our
study was to determine the prevalence and pattern of
cardiometabolic comorbidity and key determinants,
which was achieved. Finally, our study was not conducted
in a nationally representative sample of hypertensive individuals in rural areas, and the findings may not be generalised to all rural-residing hypertensive individuals aged
≥40 years in each country.
In conclusion, our study shows an alarmingly high
burden of CMM affecting one in four individuals with
hypertension from rural communities in Bangladesh, Pakistan and Sri Lanka. Central obesity had a graded, positive
association with CMM. IWI showed an inverted J-shaped
relationship with CMM, with individuals in middle SES
have a higher burden than those in the highest or lowest
SES. Our findings suggest that the current single-disease
paradigm in hypertension prevention and management
needs to be broadened and incorporate the large and
increasing burden of comorbidities in rural South Asia.
The management strategies should be customised to individual countries. Strategies to manage central obesity may
be relevant to the prevention and management of CMM
in rural South Asia.
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